Last week, readers were most interested in a story about a proposed acquisition by Abbott of Exact Sciences that would launch Abbott into the cancer testing space.

With the permit, St. Louis-based C2N can offer its PrecivityAD2 and PrecivityAD Alzheimer's blood tests to patients in New York State.

PrognomiQ announced the initial launch of its ProVue blood test while Mercy presented new data detailing the performance of its Halo lung cancer test.

The firm's new strategy revolves around adding to its test menu in an impactful way and expanding its installed base of instruments.

"Including bacterial isolates in our FDA studies was a strategic decision — it provides hospital laboratories with flexibility and ensures that QuickMIC integrates seamlessly into existing ...

The test, which runs on the BD Viper LT and BD Cor automated PCR systems, will be added to the WHO's list of prequalified IVDs for cervical cancer screening.

A slew of new studies and reports suggest that new molecular approaches may soon help reduce the global burden of tuberculosis.

Exact Sciences shareholders will receive $105 per common share as part of the deal, which is expected to close in the second quarter of 2026.

The company presented data at last week's AMP annual meeting proving the concept of its platform's applications in infectious disease and cancer.

Roche will receive rights to at least 1 billion lateral flow tests annually from Sapphiros as well as access to the company's future molecular testing technology.

The test is intended for patients with moderate to severe depression and differentiates between unipolar and bipolar depression.

With the transaction, which Bloomberg News said could be announced within the next several days, Abbott would acquire tests including Exact's Cologuard, among other tests.